Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


European Perspectives in CLL from EHA 25

Published on: 23.06.2020, 41 min.

In this webinar, Prof. Dr. Arnon Kater, Prof. Dr. Clemens Wendtner and Prof. Dr. Davide Rossi discuss three practice changing studies on CLL.

Study 1 summarised by Prof. Dr. Arnon Kater

EFFICACY OF VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY
CHRONIC LYMPHOCYTIC LEUKEMIA: PRIMARY ENDPOINT ANALYSIS OF THE INTERNATIONAL
PHASE 3B TRIAL (VENICE I)

Study 2 summarised by Prof. Dr. Clemens Wendtner

S155: FIXED-DURATION VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FOLLOW-UP OF EFFICACY AND SAFETY RESULTS FROM THE MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE 3 CLL14 TRIAL

Study 3 summarised by Prof. Dr. Davide Rossi

S 158: FIRST-LINE IBRUTINIB (IBR) + VENETOCLAX (VEN) FOR PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): EFFICACY AND SAFETY RESULTS FROM CAPTIVATE MRD COHORT

 

The webinar was independently produced and paid for by the MEDtalks Group of Companies.